APELLIS PHARMACEUTICALS INC (APLS) Stock Balance Sheet
NASDAQ:APLS - Nasdaq - US03753U1060 - Common Stock - Currency: USD
| MRQ (2024-9-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 396.86M | 351.19M | 551.80M | 640.20M | 565.80M | |||
| Marketable Securities | N/A | N/A | 0.00 | 60.40M | 311.90M | |||
| Receivables | 283.97M | 224.50M | 29.20M | 10.10M | N/A | |||
| Inventories | 121.06M | 146.36M | 85.70M | 16.30M | N/A | |||
| Other Current Assets | 32.01M | 44.29M | 52.90M | 97.10M | 39.50M | |||
| Total Current Assets | 833.90M | 766.33M | 719.50M | 824.00M | 917.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 20.44M | 21.09M | 24.90M | 26.10M | 24.50M | |||
| Other Non-Current Assets | 47.53M | 1.31M | 15.80M | 31.60M | 18.90M | |||
| Total Non-Current Assets | 67.97M | 22.40M | 40.70M | 57.80M | 43.40M | |||
| TOTAL ASSETS | 901.87M | 788.73M | 760.20M | 881.80M | 960.60M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 0.00 | 75.83M | 29.50M | 7.60M | 4.20M | |||
| Accrued Expenses | 146.63M | 134.25M | 100.80M | 107.40M | 115.60M | |||
| Accounts Payable | 42.73M | 37.52M | 37.30M | 16.90M | 8.50M | |||
| Other Current Liabilities | 1.90M | N/A | N/A | N/A | N/A | |||
| Total Current Liabilities | 191.26M | 247.59M | 167.60M | 131.80M | 128.30M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 452.25M | 332.85M | 408.40M | 534.20M | 358.80M | |||
| Other Non-Current Liabilities | 21.24M | 13.77M | 14.40M | 17.10M | 268.90M | |||
| Total Non-Current Liabilities | 473.49M | 346.62M | 422.70M | 551.30M | 627.70M | |||
| TOTAL LIABILITIES | 664.75M | 594.21M | 590.30M | 683.10M | 756.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -3.00B | -2.84B | -2.31B | -1.66B | -926.30M | |||
| Additional Paid In Capital | 3.24B | 3.04B | 2.48B | 1.86B | 1.13B | |||
| Common Shares | 12.00K | 12.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -3.14M | -2.57M | -2.50M | -2.10M | -100.00K | |||
| Shares Outstanding | 122.07M | 119.56M | 110.80M | 97.50M | 76.10M | |||
| Tangible Book Value per Share | 1.94 | 1.63 | 1.53 | 2.04 | 2.69 | |||
| Total Shareholders' Equity | 237.12M | 194.52M | 169.90M | 198.70M | 204.60M | |||
| TOTAL LIABILITIES AND EQUITY | 901.87M | 788.73M | 760.20M | 881.80M | 960.60M | |||
| Statistics | ||||||||
| Debt/Equity | 1.91 | 1.71 | 2.40 | 2.69 | 1.75 | |||
| Current Ratio | 4.36 | 3.10 | 4.29 | 6.25 | 7.15 | |||
| Return On Assets (ROA) | -27.73% | -67.02% | -85.79% | -84.65% | -35.90% | |||
| Return On Equity (ROE) | -105.47% | -271.76% | -383.87% | -375.64% | -168.57% | |||
All data in USD , ROIC based on taxRate of 0.21